Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. 1996

T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
Department of Medicine, Veterans General Hospital-Taipei, Taiwan, Republic of China.

OBJECTIVE Hepatitis D virus superinfection in hepatitis B virus carriers produces additional damage in an already injured liver. Earlier reports noted that the development of hepatocellular carcinoma may be accelerated in hepatitis D virus-superinfected patients. This study aimed to investigate the impact of hepatitis D virus on the clinical course of hepatitis B virus-associated hepatocellular carcinoma. METHODS A total of 42 consecutive hepatocellular carcinoma cases seropositive for antibody against hepatitis D virus antigen (anti-HDV) were found from 1986 to 1994; the clinical manifestations, treatment and outcomes were compared with 255 consecutive hepatocellular carcinoma cases seropositive for hepatitis B virus surface antigen but seronegative for anti-HDV. RESULTS The mean age was 60 years in both groups of patients. Other features, including sex, duration of follow-up, presence of cirrhosis or ascites, serum biochemistry, status of HBV-e antigen, and gross and microscopic tumor appearance, were not significantly different between the two groups. Though more patients in the anti-HDV-positive group underwent active treatment (operation or transcatheter arterial chemoembolization) than those in the anti-HDV-negative group (54.8% in 42 versus 34.9% in 255 cases, p = 0.02), the cumulative 4-year survival rates (9.5% versus 9.8%) were similar. For the anti-HDV-positive hepatocellular carcinoma patients, tumor size < 5 cm and active treatment were favorable prognostic predictors associated with survival > 18 months. CONCLUSIONS Hepatitis D virus superinfection does not accelerate the development of hepatocellular carcinoma. The clinical manifestations were similar, and the outcome in anti-HDV-positive patients was not worse than in the general HBV-associated hepatocellular carcinoma patients, as long as they were diagnosed at an early stage and actively treated.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003698 Hepatitis Delta Virus A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus. Delta Agent,Delta Virus,Deltavirus,Hepatitis D Virus,Delta Agents,Delta Virus, Hepatitis,Delta Viruses,Delta Viruses, Hepatitis,Deltaviruses,Hepatitis D Viruses,Hepatitis Delta Viruses
D003699 Hepatitis D INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Amazon Black Fever,Black Fever, Amazon,Delta Hepatitis,Delta Infection,Delta Superinfection,Hepatitis, Delta,Labrea Disease,Infection, Delta,Superinfection, Delta,Delta Superinfections,Disease, Labrea,Diseases, Labrea,Fever, Amazon Black,Hepatitides, Delta,Infections, Delta,Labrea Diseases,Superinfections, Delta
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis

Related Publications

T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
November 2001, Digestive diseases and sciences,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
October 2002, Zhonghua nei ke za zhi,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
January 2017, Advances in experimental medicine and biology,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
May 2022, Viruses,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
March 2021, Journal of liver cancer,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
November 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
October 1997, Zhonghua bing li xue za zhi = Chinese journal of pathology,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
April 1988, Journal of hepatology,
T I Huo, and J C Wu, and C R Lai, and C L Lu, and W Y Sheng, and S D Lee
August 2023, Journal of cellular and molecular medicine,
Copied contents to your clipboard!